- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
AN2 Therapeutics Inc (ANTX)
AN2 Therapeutics Inc stock price live, this page displays NASDAQ ANTX stock exchange data. View the ANTX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the AN2 Therapeutics Inc real time stock price chart below.
What Is the AN2 Therapeutics Inc Stock Price Today?
The AN2 Therapeutics Inc stock price today is 1.100.
What Is the Stock Symbol for AN2 Therapeutics Inc?
The stock symbol for AN2 Therapeutics Inc is ""ANTX.""
What Stock Exchange Does AN2 Therapeutics Inc Trade On?
AN2 Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is AN2 Therapeutics Inc a Good Stock to Buy?
Determining whether AN2 Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ANTX quote. (ISIN: US0373261058)
What Is the AN2 Therapeutics Inc Stock Price Today?
The AN2 Therapeutics Inc stock price today is 1.100.
What Is the Stock Symbol for AN2 Therapeutics Inc?
The stock symbol for AN2 Therapeutics Inc is ""ANTX.""
What Stock Exchange Does AN2 Therapeutics Inc Trade On?
AN2 Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is AN2 Therapeutics Inc a Good Stock to Buy?
Determining whether AN2 Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ANTX quote. (ISIN: US0373261058)
NASDAQ
Currency in USD
1.100
-0.040(-3.51%)
Closed·
After Hours
1.140+0.040(+3.63%)
·
Fair Value
An estimate of a AN2 Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.100
1.130
52 wk Range
0.870
2.731
ANTX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 13 days
More Info
Fair Value
An estimate of a AN2 Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.1001.130
52 wk Range
0.8702.731
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ANTX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a AN2 Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Neutral
Price Target
1.667
Upside
+51.52%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
AN2 Therapeutics Inc Company Profile
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company’s initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Compare ANTX to Peers and Sector
Metrics to compare | ANTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipANTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.7x | −1.0x | −0.5x | |
PEG Ratio | −0.02 | −0.02 | 0.00 | |
Price/Book | 0.5x | 0.6x | 2.6x | |
Price / LTM Sales | - | 2.5x | 3.2x | |
Upside (Analyst Target) | 75.4% | 102.5% | 40.5% | |
Fair Value Upside | Unlock | 17.3% | 4.4% | Unlock |
Analyst Ratings
1 Buy
1 Hold
1 Sell
Ratings:
3 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 1.667
(+51.52% Upside)
Earnings
Latest Release
May 13, 2025
EPS / Forecast
-0.35 / -0.25
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does AN2 Therapeutics Trade On?
AN2 Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for AN2 Therapeutics?
The stock symbol for AN2 Therapeutics is "ANTX."
What Is the AN2 Therapeutics Market Cap?
As of today, AN2 Therapeutics market cap is 33.19M.
What Is AN2 Therapeutics's Earnings Per Share (TTM)?
The AN2 Therapeutics EPS (TTM) is -1.52.
When Is the Next AN2 Therapeutics Earnings Date?
AN2 Therapeutics will release its next earnings report on 06 Aug 2025.
From a Technical Analysis Perspective, Is ANTX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has AN2 Therapeutics Stock Split?
AN2 Therapeutics has split 0 times.
How Many Employees Does AN2 Therapeutics Have?
AN2 Therapeutics has 22 employees.
What is the current trading status of AN2 Therapeutics (ANTX)?
As of 25 Jul 2025, AN2 Therapeutics (ANTX) is trading at a price of 1.10, with a previous close of 1.14. The stock has fluctuated within a day range of 1.10 to 1.13, while its 52-week range spans from 0.87 to 2.73.
What Is AN2 Therapeutics (ANTX) Price Target According to Analysts?
The average 12-month price target for AN2 Therapeutics is USD1.66667, with a high estimate of USD2 and a low estimate of USD1. 1 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an +51.52% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.